Compare EPR Properties (EPR) vs Moderna, Inc. (MRNA) Price & Performance

EPR Properties (EPR) trades at $61.41, up 1.67% in the last session, with a bearish technical signal despite strong Q2 2026 FFO beating estimates. The company reported revenue growth to $699 million in 2026, though net income dipped to $263 million, and maintains a high gross margin of 91.41%. Recent news highlights dividend declarations and a new $1.6 billion credit facility, supporting its experiential real estate focus.

Outlook is mixed: analyst consensus favors 'Hold' with a $65.30 price target, indicating modest upside, but technical indicators and a slight earnings miss in Q1 2026 pose risks. Opportunities include dividend growth and portfolio diversification, while risks involve investing cash flow volatility and sector competition.

Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.

The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.